Targeted delivery of therapeutic oligonucleotides through conjugation to a homing ligand enables modulation of disease targets in specific cell types that are intractable to small molecules and antibodies.
The homing ligand can a small molecule, peptide, carbohydrate or aptamer. The linker chemistry is designed so that the conjugate cleavage occurs in the desired cell type to deliver the drug where it can modulate the disease-causing target. The linker design is also critical to limiting the risk of toxicity driven by the linker fragments that may be released upon conjugate cleavage or degradation.
AstraZeneca is one of the world’s most exciting bio-pharmaceutical companies. Be inspired by the possibilities of science to make a difference and discover what you can do.
Partner with us
We know that innovation doesn’t happen in isolation, so we partner with others to access the best science and contribute complementary technologies, know-how and molecules.
Learn about us
Our IMED Biotech unit is committed to driving scientific advances in small molecules, oligonucleotides and other emerging technology platforms to push the boundaries of medical science.